Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDR132L versus placebo in heart failure with reduced or mildly reduced ejection fraction and left ventricular hypertrophy
NL-OMON60922Phase 2Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and heart failure with mid-range ejection fraction (HFmrEF) comparing CDR132L + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Change in normalized miR-132 from baseline to week 24. Started Aug 2025; status: active, not recruiting.
02
Drugs
CDR132L
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on NL-OMON60922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60922.